Browsing Tag
synthetic lethality
3 posts
Gilead Sciences acquires RP-3467 from Repare Therapeutics to strengthen synthetic lethality pipeline
Gilead buys RP-3467 from Repare for up to $30M, boosting Repare’s shareholder payout ahead of its Xeno acquisition. Find out what this means for oncology.
GSK walks away from IDEAYA cancer assets: What went wrong with synthetic lethality?
GSK ends its partnership with IDEAYA on two oncology assets. Find out what this means for IDEAYA’s pipeline, stock sentiment, and future partnerships.
Repare Therapeutics (RPTX) to be acquired by XenoTherapeutics in CVR-backed buyout
Repare Therapeutics to be acquired by XenoTherapeutics with $1.82/share cash payout and long-term CVR upside. Find out what this means for investors.